Ressource pédagogique : Dr Antoine Guillon - Flagellin-based antibacterial strategy and clinical perspectives

Informations pratiques sur cette ressource

Description de la ressource pédagogique

Description (résumé)

Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance and the curative failure. Targeting the innate immune system is an underexploited area of drug discovery for infectious diseases. The JC Sirard’s research team (Lille, Fr) has demonstrated that the respiratory tract administration of a Toll-like receptor 5 agonist (the immunomodulatory flagellin) activates innate immunity in the lung airway epithelium and enhances the therapeutic outcome (relative to low doses of antibiotic alone) in the context of pneumonia caused by antibiotic-susceptible S. pneumoniae, in the mouse. The presentation will describe a European consortium (FAIR project) which plans to bridge experimental data to human trial by developing a TLR-agonist as nebulized adjunct therapy approach. If this adjunct therapy approach can ultimately be translated into humans and extended to other bacterial pathogens (especially antibiotic-resistant bacteria) and various classes of antibiotics, the treatment of pneumonia would be transformed.  

"Domaine(s)" et indice(s) Dewey

• Maladies des poumons (hypertension artérielle pulmonaire, hypertension pulmonaire, maladie obstructive respiratoire chronique, maladies respiratoires, ouvrages généraux sur les maladies des bronches et des poumons) (616.24)

Thème(s)